Beacon Investment Advisory Services Inc. Boosts Stock Position in Kenvue Inc. (NYSE:KVUE)

Beacon Investment Advisory Services Inc. boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 2.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 241,990 shares of the company’s stock after acquiring an additional 6,296 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Kenvue were worth $5,166,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of KVUE. Leo Wealth LLC lifted its position in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after purchasing an additional 481 shares in the last quarter. Alerus Financial NA increased its stake in Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after buying an additional 491 shares during the period. Massmutual Trust Co. FSB ADV lifted its holdings in Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after buying an additional 492 shares in the last quarter. Kiley Juergens Wealth Management LLC lifted its holdings in Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after buying an additional 500 shares in the last quarter. Finally, Wolff Wiese Magana LLC boosted its position in Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Down 0.3 %

NYSE:KVUE opened at $20.73 on Thursday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock’s 50 day simple moving average is $22.31 and its 200-day simple moving average is $21.75. The firm has a market cap of $39.75 billion, a P/E ratio of 37.70, a PEG ratio of 2.00 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter last year, the business earned $0.31 EPS. The business’s revenue was down .4% on a year-over-year basis. Equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.95%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Citigroup dropped their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Barclays lowered their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Bank of America upped their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.